Forecasts data is unavailable for this security.

Consensus recommendation

As of Jul 22, 2016, the consensus forecast amongst 27 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy4
Outperform6
Hold15
Underperform2
Sell0

Share price forecast

The 24 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,660, with a high estimate of 2,000 and a low estimate of 1,272. The median estimate represents a -1.66% decrease from the last price of 1,688.
High18.5%2,000
Med-1.7%1,660
Low-24.6%1,272

Dividends

In 2015, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 22 analysts covering the company expect dividends of 0.81 GBP for the upcoming fiscal year, an increase of 1.13%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Jul 27, 2016, GlaxoSmithKline plc reported 2nd quarter 2016 earnings of 0.245 per share.
The next earnings announcement is expected on Oct 26, 2016.
Average growth rate+11.19%
GlaxoSmithKline plc reported annual 2015 earnings of 0.757 per share on Feb 03, 2016.
Average growth rate-9.56%
More ▼

Revenue history & estimates

GlaxoSmithKline plc had 2nd quarter 2016 revenues of 6.53bn. This bettered the 6.34bn consensus of the 12 analysts covering the company. This was 10.94% above the prior year's 2nd quarter results.
Average growth rate+2.65%
GlaxoSmithKline plc had revenues for the full year 2015 of 23.92bn. This was 3.99% above the prior year's results.
Average growth rate-3.11%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.